data + articles · 6 listed
newest 2022spec sheet11 rows
Dopamantine is an obscure dopamine prodrug: dopamine linked through an amide bond to a lipophilic adamantane (fat-soluble cage) group. The idea behind such molecules is to mask dopamine, which on its own cannot cross the blood-brain barrier, and let the body cleave off the carrier to release dopamine inside the brain for Parkinson's disease. Dopamantine itself has essentially no published pharmacology or clinical data; it is best understood as one entry in the broad, still-experimental class of dopamine and levodopa prodrugs.
- In theory delivers dopamine past the blood-brain barrier
- Amide linkage is more chemically stable than ester prodrugs
- Illustrates the adamantane carrier approach to brain drug delivery
- Part of an actively researched prodrug class for Parkinson's
- No documented human safety data
- Dopaminergic effects on blood pressure and nausea (theoretical)
- Unknown release kinetics and brain penetration
- Research-chemical status; purity unverified
Mechanism
given directly is useless for Parkinson's because it does not cross the and is rapidly metabolized; the standard workaround is a , a masked form that travels better and then releases dopamine where it is needed [2][3]. Dopamantine follows the amide- strategy, joining to an adamantyl carrier so the molecule is more (fat-soluble) and, in principle, more stable and better able to reach the brain, where enzymes would hydrolyze the amide to free dopamine [2][4].
Amide-linked prodrugs are generally more chemically stable than ester versions but can be slower to release the active drug [2]. Related work has explicitly used and adamantane-amine cargo on brain-targeting carriers [1], and other -amide conjugates have been made and tested [5]. For dopamantine specifically the release kinetics, brain penetration, and activity are not documented, so any account of how well it works is speculative.
receptor fingerprint
(as released drug)prodrug donor
lipophilic carrier strategy (presumed)
Safetyrisks and cautions, not medical advice
There is no meaningful human or animal safety data for dopamantine as a named compound. General cautions for dopaminergic prodrugs apply in theory: releasing dopamine can affect blood pressure, heart rate, nausea, and, in a Parkinson's context, movement and psychiatric side effects. Because the compound is essentially unstudied, purity, dosing, and behavior in the body are all unknown, and it should be regarded as a research chemical rather than a therapy. Not medical advice.
Subjective profileweighing the evidence above
Not worth touching. There is essentially no published pharmacology for the compound itself, so purity, dose, release kinetics and brain penetration are all unknown. It illustrates the adamantane prodrug idea rather than demonstrating it.
Resources
This entry is here for reference.
Research
- 2008first citedDesign, synthesis and biological evaluation of glutathione peptidomimetics as components of ant…
- 2022most recentDevelopment of Prodrugs for Treatment of Parkinson's Disease: New Inorganic Scaffolds for Blood…
- 1.Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs.
- 2.Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease.
- 3.Development of Prodrugs for Treatment of Parkinson's Disease: New Inorganic Scaffolds for Blood-Brain Barrier Permeation.
- 4.Solid lipid microparticles for the stability enhancement of a dopamine prodrug.
- 5.[Cerebrovascular pharmacology of separate and combined vascular pathology of brain and heart].
- 6.The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson's disease.
6 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Is dopamantine an actual medicine?
No. It is an obscure, largely unstudied dopamine prodrug concept, not an approved or well-characterized drug.
Why attach dopamine to an adamantane group?
Dopamine cannot cross the blood-brain barrier on its own. A lipophilic adamantyl carrier is meant to help the molecule reach the brain, where the bond is cleaved to release dopamine.
Does it work?
There is no published evidence showing that dopamantine specifically works; the supporting science is about the broader dopamine-prodrug strategy, not this exact compound.
Adverse effects
- No documented human safety data
- Dopaminergic effects on blood pressure and nausea (theoretical)
- Unknown release kinetics and brain penetration
- Research-chemical status; purity unverified